BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
- Conditions
- Chronic Lymphocytic LeukemiaFollicular LymphomaAcute Myelogenous LeukemiaDiffuse Large B-Cell Leukemia
- Interventions
- Drug: BMS-936564 (Anti-CXCR4)
- First Posted Date
- 2010-05-11
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 96
- Registration Number
- NCT01120457
- Locations
- 🇺🇸
Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States
🇺🇸The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸Uc San Diego Moores Cancer Center, La Jolla, California, United States
Safety Study of BMS-823778 in Subjects With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 62
- Registration Number
- NCT01111955
- Locations
- 🇺🇸
Capital Clinical Reserch Center, Olympia, Washington, United States
🇺🇸Farid Marquez, Md, Hialeah, Florida, United States
🇨🇦Local Institution, Quebec, Canada
Safety Study of BMS-823778 in Subjects With Hypercholesterolemia
- Conditions
- Dyslipidemia
- Interventions
- Drug: BMS-823778Drug: Placebo
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT01112423
- Locations
- 🇺🇸
Pra International, Lenexa, Kansas, United States
🇺🇸Sterling Research Grp, Ltd., Cincinnati, Ohio, United States
🇺🇸Osborne Research Center, Little Rock, Arkansas, United States
Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 87
- Registration Number
- NCT01108705
- Locations
- 🇨🇳
Local Institution, Taoyuan, Taiwan
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Drug: BMS-820132Drug: Placebo
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 56
- Registration Number
- NCT01105429
- Locations
- 🇺🇸
Profil Institute For Clinical Research, Inc. (Picr), Chula Vista, California, United States
🇺🇸Elite Research Institute, Miami, Florida, United States
🇺🇸Clinical Pharmacology Of Miami Inc., Miami, Florida, United States
PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 82
- Registration Number
- NCT01099579
- Locations
- 🇹🇭
Local Institution, Bangkok, Thailand
A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 69
- Registration Number
- NCT01096043
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
🇺🇸Florida Hospital Transplant Center, Orlando, Florida, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Safety Study of Abatacept in Sweden
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-03-29
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 92635
- Registration Number
- NCT01094795
Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure
- Conditions
- Heart Failure
- Interventions
- Drug: CXL-1020Drug: CXL-1020 Doses for Echo Cohort BDrug: Placebo for CXL-1020 Cohort 1Drug: Placebo for CXL-1020 Cohort 2Drug: CXL-1020 Dose for Echo Cohort A
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28
- Registration Number
- NCT01092325
- Locations
- 🇺🇸
Orange County Clinical Research Center, Tustin, California, United States
Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20000
- Registration Number
- NCT01088360